STATES PATENT (IND TRADEMARK) Atty Dkt. 559-354 In re Patent Application of Group Art Unit: Unassigned Christensen et al Serial No. 10/018,604 Examiner: Unassigned Date: September 6, 2002 Filed: December 14, 2001 PROCESS FOR THE ENZYMATIC MODIFICATION OF PECTIN Title: Assistant Commissioner for Patents Washington, DC 20231 Sir: RESPONSE/AMENDMENT/LETTER This is a response/amendment/letter in the above-identified application and includes an attachment which is hereby incorporated by reference and the signature below serves as the signature to the attachment in the absence of any other signature thereon. Fees are attached as calculated below: Total effective claims after amendment minus highest number \$ 0.00 \$ 18.00 previously paid for 20 (at least 20) =minus highest number Indépendent claims after amendment 0.00 previously paid for (at least 3) =O X \$ 84.00 3 If proper multiple dependent claims now added for first time, add \$280.00 (ignore improper) 0.00 Petition is hereby made to extend the current due date so as to cover the filing date of this \$ 0.00 paper and attachment(s) (\$110.00/1 month; \$400.00/2 months; \$920.00/3 months) \$ 0.00 Terminal disclaimer enclosed, add \$ 110.00 First/second submission after Final Rejection pursuant to 37 CFR 1.129(a) (\$740.00) \$ 0.00 Please enter the previously unentered , filed ☐ Submission attached Subtotal 0.00 -\$ 0.00 If "small entity," then enter half (1/2) of subtotal and subtract Applicant claims "small entity" status.

Statement filed herewith \$ 0.00 Rule 56 Information Disclosure Statement Filing Fee (\$180.00) \$ 0.00 Assignment Recording Fee (\$40.00) Other: attached: copy of Notice of Address Change and Power to underigned filed August 29, 2002 with 0.00 Amendment, Notification of August 6, 2002, Statement, paper and computer readable copies of Sequence Listing TOTAL FEE ENCLOSED 0.00 The Commissioner is hereby authorized to charge any deficiency, or credit any overpayment, in the fee(s) filed, or asserted to be filed, or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our Account No. 14-1140. A duplicate copy of this sheet is attached. 1100 North Glebe Road, 8th Floor NIXON & VANDERHYË P.C. Arlington, Virginia 22201-4714 By Atty: B. J. Sadoff, Reg. No. 36,663 Telephone: (703) 816-4000 Facsimile: (703) 816-4100

Signature:

BJS:b



United States Patent and Trademark Office

Correspondent for Patines. Box PCT United States Patent and Tracemerk Office Washington, D.C. 2023

week u NOB 3.4

U.S. APPLICATION NUMBER NO. FIRST NAMED APPLICANT ATTY, DOCKET NO.

10/018,604 Tovc Christensen DYOU27.001APC

INTERNATIONAL APPLICATION NO

PCT/IB00/00869

20995 KNOBBE MARTENS OLSON & BEAR LLP 620 NEWPORT CENTER DRIVE SIXTEENTH FLOOR NEWPORT BEACH, CA 92660

1A FILINO DATE PRIORITY DATE 06/15/2000 06/17/1999

CONFIRMATION NO. 8385
371 FORMALITIES LETTER
OC000000008570234

Date Mailed: 08/06/2002

NOTIFICATION OF DEFECTIVE RESPONSE

The following items have been submitted by the applicant or the IB to the United States Patent and Trademark Office as an Elected Office (37 CFR 1.495):

- U.S. Basic National Fee
- Priority Document
- Biochemical Sequence Listing
- Copy of IPE Report
- · Copy of references cited in ISR
- Copy of the International Application
- Copy of the International Search Report
- Information Disclosure Statements
- Oath or Declaration
- Preliminary Amendments
- Request for Immediate Examination

The following items MUST be furnished within the period set forth below in order to complete the requirements for acceptance under 35 U.S.C. 371:

Applicant is required to complete the response within a time limit of ONE MONTH from the date of this Notification or within the time remaining in the response set forth in the Notification of Missing Requirements, whichever is the longer. No extension of this time limit may be granted under 37 CFR 1.136, but the period for response set in the Notification of Missing Requirements may be extended under 37 CFR 1.136(a).

The following items MUST be furnished within the period set forth below:

- The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the
 requirements for such a disclosure as set forth in 37 CFR 1.821-1.825 for the following reason(s):
 - A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 CFR 1.821(e).

■ APPLICANT MUST PROVIDE:

- An initial or substitute computer readable form (CRF) of the "Sequence Listing."
- A statement that the contents of the paper or compact disc and the computer readable form are the same and, where applicable, include no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b) or 1.825(d).
- For questions regarding compliance to 37 CFR 1.821-1.825 requirements, please contact:
 - For Rules Interpretation, call (703) 308-4216
 - To Purchase Patentin Software, call (703) 306-2600
 - For Patentin Software Program Help, call (703) 306-4119 or e-mail at patin21help@uspto.gov or patin3help@uspto.gov
 - A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 CFR 1.821(e).

Applicant is reminded that any communications to the United States Patent and Trademark Office must be mailed to the address given in the heading and include the U.S. application no. shown above (37 CFR 1.5)

A copy of this notice MUST be returned with the response.

VONDA M WALLACE

Telephone: (703) 305-3736

PART 1 - ATTORNEY/APPLICANT COPY

U.S. APPLICATION NUMBER NO	INTERNATIONAL APPLICATION NO.	ATTY. DOCKET NO.
10/018,604	PCT/IB00/00869	DYOU27.001APC

FORM PCT/DO/EO/916 (371 Formalities Notice)